KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $247,314 | +23.4% | 14,238 | 0.0% | 0.05% | +19.5% |
| Q2 2023 | $200,471 | +30.9% | 14,238 | 0.0% | 0.04% | +28.1% |
| Q1 2023 | $153,201 | -28.2% | 14,238 | 0.0% | 0.03% | -28.9% |
| Q4 2022 | $213,285 | +16.5% | 14,238 | 0.0% | 0.04% | -2.2% |
| Q3 2022 | $183,000 | +23.6% | 14,238 | -6.6% | 0.05% | +31.4% |
| Q2 2022 | $148,000 | -13.5% | 15,238 | -11.6% | 0.04% | +2.9% |
| Q1 2022 | $171,000 | -15.8% | 17,238 | 0.0% | 0.03% | -10.5% |
| Q4 2021 | $203,000 | -19.8% | 17,238 | -22.5% | 0.04% | -26.9% |
| Q3 2021 | $253,000 | -31.6% | 22,238 | -16.2% | 0.05% | -31.6% |
| Q2 2021 | $370,000 | -23.9% | 26,538 | +1.1% | 0.08% | -27.6% |
| Q1 2021 | $486,000 | +4.7% | 26,238 | 0.0% | 0.10% | -8.7% |
| Q4 2020 | $464,000 | – | 26,238 | +20.9% | 0.12% | – |
| Q3 2020 | $0 | -100.0% | 21,700 | +10.2% | 0.00% | -100.0% |
| Q2 2020 | $502,000 | +64.6% | 19,700 | 0.0% | 0.15% | +35.5% |
| Q1 2020 | $305,000 | – | 19,700 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |